Neuren Pharmaceuticals Limited (ASX:NEU)

Market Cap	1.61B +0.7%
Revenue (ttm)	64.65M -70.2%
Net Income	30.44M -78.6%
EPS	0.23 -78.6%
Shares Out	126.32M
PE Ratio	54.83
Forward PE	135.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	929,248
Open	12.70
Previous Close	12.76
Day's Range	12.07 - 12.83
52-Week Range	11.00 - 22.99
Beta	1.59
Analysts	Strong Buy
Price Target	23.45 (+92.21%)
Earnings Date	Aug 28, 2026

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NEU

Financial Performance

In 2025, Neuren Pharmaceuticals's revenue was 64.65 million, a decrease of -70.18% compared to the previous year's 216.83 million. Earnings were 30.44 million, a decrease of -78.57%.

Analyst Summary

According to 6 analysts, the average rating for NEU stock is "Strong Buy." The 12-month stock price target is $23.45, which is an increase of 92.21% from the latest price.

Price Target

$23.45

(92.21% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 26, 2026

Data Sources Report a data error